Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06719219 · ClinicalTrials.gov registry record · Phase 1
A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.
A Phase 1 study of Staphylococcus (S.) Aureus Infection, sponsored by LimmaTech Biologics.
- Completed
- Registry status
- Phase 1
- Development phase
- 129
- Enrollment target
- 1
- Study location
NCT06719219: Completed Phase 1 study of Staphylococcus (S.) Aureus Infection, sponsored by LimmaTech Biologics.
NCT06719219 is a Phase 1 study of Staphylococcus (S.) Aureus Infection that has completed, run by LimmaTech Biologics. The registered enrollment target is 129 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (115% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06719219, a Phase 1 study of Staphylococcus (S.) Aureus Infection, has completed, sponsored by LimmaTech Biologics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 129 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, the candidate vaccine LTB-SA7 will be tested for safety and immunogenicity in healthy adults.
Primary Outcome
Occurrence and severity of solicited local and systemic AEs during 7 days after each dose (i.e., day of vaccination and the 6 subsequent days) in all participants by intervention group.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL LTB-SA7
Study Locations (1)
Maryland
- Naval Medical Research Command Clinical Trial Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2025-01-07 |
| Est. Completion | 2026-03-04 |
| Phase | Phase 1 |
What the finished NCT06719219 record still lists
NCT06719219 is an interventional study that assigns participants to a tested intervention. The registered 129 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (115% higher).
The record links to 1 condition, with Staphylococcus (S.) Aureus Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06719219 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06719219 about?
NCT06719219 is a clinical study titled "A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.". In this study, the candidate vaccine LTB-SA7 will be tested for safety and immunogenicity in healthy adults.
What is the current status of trial NCT06719219?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 129 participants. The study started on 2025-01-07. Estimated completion is 2026-03-04.
What conditions does trial NCT06719219 study?
This clinical trial studies the following conditions: Staphylococcus (S.) Aureus Infection.
What interventions are being tested in trial NCT06719219?
The interventions under investigation include: Placebo (BIOLOGICAL), LTB-SA7 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06719219?
This trial is sponsored by LimmaTech Biologics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06719219 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06719219's enrollment target sits among peer trials
129 451st of 2000 higher than 1,549 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03619850 · 129 participants · Phase 3
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- NCT05704361 · 129 participants · Phase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
- NCT05919849 · 129 participants · Phase 1
Supporting Parents in Affirming Their Children's Experiences of Stigma
- NCT06313749 · 129 participants · NA
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI